Rapamycin

Key Research Papers and Clinical Trials

Current research on rapamycin spans multiple therapeutic areas, though specific details about rapamycin's direct effects are limited in the available evidence.

Basic Science Research

Several recent papers explore rapamycin's target pathway, mTOR, in various disease contexts. A 2026 review in The Journal of Heart and Lung Transplantation examines mapping the mTOR pathway in lung transplantation, suggesting potential for biomarker-driven precision therapy approaches, though specific study designs and sample sizes are not detailed in the available abstracts.

Research published in The Journal of Cell Biology (2026) investigates how Rag GTPases and mTORC1 regulate intestinal stem cell activity in response to nutrient availability, indicating rapamycin's pathway plays a role in cellular metabolism and stem cell function. A review in Cells (2026) discusses the orchestration of autophagy and senescence, highlighting kinases in these processes - pathways that rapamycin is known to influence.

Additional studies touch on immuno-metabolic reprogramming in pulmonary fibrosis and carrier-free nanoassembly approaches for enhanced chemo-immunotherapy, though rapamycin's specific role in these contexts requires further clarification.

Clinical Trials

The clinical trial landscape shows rapamycin being investigated across diverse therapeutic areas:

Cancer Research: A completed Phase 1 study (NCT01920061) examined PF-05212384 (an mTOR inhibitor) in combination with other anti-tumor agents and cisplatin in triple-negative breast cancer patients, though results are not yet available.

Pediatric Applications: A Phase 2 safety study (NCT06308445) for rapamycin use in children with familial adenomatous polyposis is planned but not yet recruiting.

Cardiovascular Applications: A registry trial (NCT04179045) is evaluating the Bioheart rapamycin drug-eluting bioresorbable coronary stent system, though recruitment has not yet begun. Additionally, a Phase 3 study (NCT04433572) is currently recruiting patients to examine temsirolimus (a rapamycin analog) delivered adventitially to improve angioplasty and atherectomy outcomes in below-the-knee revascularization.

Hematologic Malignancies: A Phase 1 trial (NCT00473551) investigating anti-third party T lymphocytes with nonmyeloablative stem cell transplantation for indolent lymphoid malignancies was terminated.

The available evidence suggests ongoing research interest in rapamycin and its analogs across multiple therapeutic areas, though many studies are in early phases or planning stages. More detailed results from completed trials would be needed to fully assess clinical efficacy and safety profiles.

Note: This synthesis is based on available abstracts and trial listings. Specific study methodologies, sample sizes, and detailed results may require access to full publications for complete evaluation.